Abcam (OTCMKTS:ABCZY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, January 12th.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Shares of Abcam (OTCMKTS:ABCZY) opened at $17.88 on Friday. Abcam has a one year low of $10.20 and a one year high of $18.06.
TRADEMARK VIOLATION NOTICE: “Abcam (ABCZY) Rating Lowered to Hold at Zacks Investment Research” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/04/abcam-abczy-lowered-to-hold-at-zacks-investment-research.html.
Get a free copy of the Zacks research report on Abcam (ABCZY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.